Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antibody Actions01:26

Antibody Actions

1.7K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.7K
Immunoprecipitation01:20

Immunoprecipitation

6.3K
Immunoprecipitation, or IP, is a widely used technique that employs protein-antibody interactions to isolate proteins or protein complexes in their native state for studying protein-protein interactions, quaternary structures, or supramolecular complexes. Various modifications of the technique, including chromatin IP, cross-linking IP, and fluorescence IP, are commonly used.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
6.3K
Antibody Structure01:10

Antibody Structure

62.3K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
62.3K
Hybridoma Technology01:31

Hybridoma Technology

16.4K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
16.4K
Antibody Structure and Classes01:25

Antibody Structure and Classes

7.4K
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
7.4K
Phase II Conjugation Reactions: Overview01:14

Phase II Conjugation Reactions: Overview

500
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
500

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BAL-derived extracellular vesicles to test ex vivo for endothelial injury in HIV patients on antiretroviral therapy.

American journal of respiratory and critical care medicine·2026
Same author

Multivalent Tranexamic Acid (TXA) and Benzamidine Derivatives for Serine Protease Inhibition.

ACS pharmacology & translational science·2025
Same author

Determining the Effects of Varying Blood Storage Conditions on Clot Formation and Digestion Under Shear.

MedComm - biomaterials and applications·2025
Same author

Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model.

Journal of visualized experiments : JoVE·2024
Same author

Exploring microplastic impact on whole blood clotting dynamics utilizing thromboelastography.

Frontiers in public health·2023
Same author

Real-time tracking of fibrinolysis under constant wall shear and various pulsatile flows in an in-vitro thrombolysis model.

Bioengineering & translational medicine·2023
Same journal

Integrating fab phage and yeast display through seamless transfer of paired heavy- and light-chain libraries for efficient antibody discovery.

Antibody therapeutics·2026
Same journal

Antibody-oligonucleotide conjugates: an emerging modality for precision RNA therapeutics.

Antibody therapeutics·2026
Same journal

Novel ADC and γδ T cell engager targeting CDH17 for the therapy of gastrointestinal cancers.

Antibody therapeutics·2026
Same journal

TROP2 antibody-drug conjugate: unique epitope engagement drives differentiated efficacy.

Antibody therapeutics·2026
Same journal

The evolving landscape of enzymatic technologies for precision synthesis of antibody-drug conjugates.

Antibody therapeutics·2026
Same journal

Cytotoxic activity and safety characterization of IMV-M™, a MUC16 × DR5 bispecific antibody.

Antibody therapeutics·2026
See all related articles

Related Experiment Video

Updated: Nov 7, 2025

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates
08:47

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates

Published on: March 6, 2019

9.7K

Antibody conjugation and formulation.

Nathan J Alves1

  • 1Department of Emergency Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.

Antibody Therapeutics
|April 30, 2021
PubMed
Summary
This summary is machine-generated.

Antibody-drug conjugates (ADCs) present formulation challenges due to high concentrations and viscosity. This review explores conjugation techniques and formulation strategies for accessible administration routes like subcutaneous injection.

Keywords:
antibody-drug conjugatesconjugationformulationhigh concentrationsite-specific

More Related Videos

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

7.9K
Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
10:35

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

3.7K

Related Experiment Videos

Last Updated: Nov 7, 2025

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates
08:47

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates

Published on: March 6, 2019

9.7K
Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

7.9K
Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
10:35

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

3.7K

Area of Science:

  • Biopharmaceutical Formulation
  • Drug Delivery Systems
  • Antibody Engineering

Background:

  • Current monoclonal antibodies face formulation challenges including high concentrations, viscosity, and limited administration routes (e.g., intravenous infusion).
  • The increasing complexity of antibody targets and novel antibody conjugates necessitates advanced formulation strategies.
  • Traditional intravenous administration of antibodies is demanding and limits accessibility.

Purpose of the Study:

  • To review antibody conjugation techniques for antibody-drug conjugates (ADCs).
  • To discuss formulation demands for high-concentration clinical applications of ADCs.
  • To explore alternative administration routes beyond intravenous infusion.

Main Methods:

  • Literature review of site-specific and non-site-specific antibody conjugation methods.
  • Analysis of formulation requirements for ADCs at high concentrations.
  • Examination of challenges and opportunities for subcutaneous and intramuscular delivery of ADCs.

Main Results:

  • Various conjugation strategies impact ADC properties and formulation feasibility.
  • High-concentration formulations are critical for advanced delivery methods.
  • Subcutaneous and intramuscular routes offer potential for improved patient accessibility.

Conclusions:

  • Effective ADC formulation requires careful consideration of conjugation methods and delivery routes.
  • Overcoming formulation hurdles is key to enabling wider clinical implementation of ADCs.
  • Advancements in conjugation and formulation will support the development of next-generation ADCs for diverse therapeutic applications.